Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Archives of Medical Research

Volumn 45, Issue 7, 2014, Pages 580-588

  Jia, Xiaobo ^a   Liu, Jiao ^a   Gao, Yingtang ^b   Huang, Yong ^a   Du, Zhi ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Third Central Hospital Jintang Road   (China)

^c Tianjin Third Central Hospital   (China)

Author keywords

Diagnostic accuracy; Glypican 3; Hepatocellular carcinoma; Serum

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; TUMOR MARKER; GLYPICAN; GPC3 PROTEIN, HUMAN;

ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; META ANALYSIS; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERUM; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84915763770     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.11.002     Document Type: Article

References (42)

1. Venook A.P., Papandreou C., Furuse J., et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(suppl 4):5-13.
2. Kawano Y., Sasaki A., Kai S., et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008, 15:1670-1676.
3. Spangenberg H.C., Thimme R., Blum H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006, 26:385-390.
4. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
5. Yamauchi N., Watanabe A., Hishinuma M., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18:1591-1598.
6. Nakatsura T., Yoshitake Y., Senju S., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
7. Chen I.P., Ariizumi S., Nakano M., et al. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014, 49:117-125.
8. Yan B., Wei J.J., Qian Y.M., et al. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol 2011, 15:162-169.
9. Whiting P.F., Rutjes A.W.S., Westwood M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
10. Zamora J., Abraira V., Muriel A., et al. Meta-disc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
11. Suzuki M., Sugimoto K., Tanaka J., et al. Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 2010, 30:5055-5061.
12. Yasuda E., Kumada T., Toyoda H., et al. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 2010, 40:477-485.
13. Filmus J., Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004, 8:207-212.
14. Nishimura Y., Nakatsura T., Senju S. Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi 2008, 31:383-391.
15. Ibrahim G.H., Mahmoud M.A., Aly N.M. Evaluation of circulating transforming growth factor-beta1, glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. Mol Biol Rep 2013, 40:7069-7075.
16. Saad Y., El-Serafy M., Eldin M.S., et al. New genetic markers for diagnosis of hepatitis C related hepatocellular carcinoma in Egyptian patients. J Gastrointest Liver Dis 2013, 22:419-425.
17. Yan D., He Q., Chen Y., et al. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 2011, 25:113-117.
18. Man X.B., Tang L., Zhang B.H., et al. Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int 2005, 25:962-966.
19. Li P., Zhai Y., Li N., et al. Diagnostic value of serum AFP alone or in combination with glypican 3, VEGF or IGF-II for patients with primary hepatocellular carcinoma. World J Gastroenterol 2010, 16:4410-4415.
20. Yao M., Yao D.F., Bian Y.Z., et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2011, 10:289-294.
21. Bian Y.Z., Yao D.F., Zhang C.G., et al. Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2011, 19:260-265.
22. Tangkijvanich P., Chanmee T., Komtong S., et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010, 25:129-137.
23. Chen M., Li G., Yan J., et al. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 2013, 423:105-111.
24. Özkan H., Erdal H., Koçak E., et al. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 2011, 25:350-353.
25. Youssef M.F., El-Sharkawy S.L., Abbas N.F., et al. Clinical utility of glypican- 3 in hepatocellular carcinoma. Int J Integr Biol 2010, 10:41-47.
26. Qiao S.S., Cui Z.Q., Gong L., et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2010, 58:1718-1724.
27. Capurro M., Wanless I.R., Sherman M., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
28. Hippo Y., Watanabe K., Watanabe A., et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004, 64:2418-2423.
29. Li B., Liu H., Shang H.W., et al. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci 2013, 13:703-709.
30. Beale G., Chattopadhyay D., Gray J., et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8:200.
31. Liu H., Li P., Zhai Y., et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010, 16:4410.
32. Yao M., Yao D.F., Bian Y.Z., et al. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2013, 12:171-179.
33. Abdelgawad I.A., Mossallam G.I., Radwan N.H., et al. Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?. Asian Pac J Cancer Prev 2013, 14:7345-7349.
34. Moety A.A.A.E., Moety H.A.A.E., Rostom Y., et al. Glypican-3 amino terminal marker for early detection of HCC. Hep Int 2011, 5:435.
35. Yu J.P., Ma Q., Zhang B., et al. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci China Life Sci 2013, 56:234-239.
36. Zhang Q., Xiao Q., Lin Z., et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 2010, 43:1003-1008.
37. Nakatsura T., Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 2005, 19:71-77.
38. Akutsu N., Yamamoto H., Sasaki S., et al. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol 2010, 16:3521.
39. Wang W., Zhao L.J., Wang Y., et al. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark 2012, 11:29-39.
40. Cleophas T.J., Zwinderman A.H. Meta-analyses of diagnostic studies. Clin Chem Lab Med 2009, 47:1351-1354.
41. Witjes C.D., van Aalten S.M., Steyerberg E.W., et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2013, 7:59-64.
42. Song F., Khan K.S., Dinnes J., et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002, 31:88-95.